Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by farmerjaneon Nov 16, 2020 12:00pm
139 Views
Post# 31906873

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:hope

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:hopeBillions have been spent on alzheimers trials, reasearch but they can't get any takers for pmn310 into the clinic for 15 million? Not buying the Biogen theory, there trial caused all kinds of interest obviously pharma not interested pmn 310, or we would already be in the clinic.

Need to clean up there webpage, Homepage Corporate update Nov, 9, 2020 really Septembers with some red lining. Homepage quick link fact sheet October, 2019, Investors quick link fact sheet updated Sept 2020, actual Sept Corporate update.
<< Previous
Bullboard Posts
Next >>